Site growth

How to negotiate a clinical trial budget as a site

Two professionals negotiating across a glass table at dusk with city lights behind them
Short answerNegotiate a clinical trial budget by building your own cost estimate from the protocol first, then pushing on the lines that decide whether the study makes money: a nonrefundable startup fee, screen failure payments that match expected failure rates, recruitment funding, overhead, payment frequency, and holdback. SCRS survey data shows these are where sites most often lose money.

Why do sites need to negotiate at all?

Because the first budget offer rarely covers real costs. SCRS reports 88% of sites say screen failures are not sufficiently covered (SCRS), 42% say screen failure terms never or rarely cover actual screen fails, and 53% regularly pay for recruitment from their own funds (SCRS). 38% of sites saw profits decline in 2023 (SCRS).

Step one: build your internal budget first

Read the full protocol, estimate the actual cost of every visit and procedure, and compare it with what the sponsor proposes, using conservative enrollment assumptions (UNC TraCS). Without your own number, you are negotiating blind.

Step two: negotiate the lines that matter

  • Nonrefundable startup fee. SCRS describes it as covering costs incurred before enrollment, such as feasibility review, confidentiality and contract review, budget development, and IRB preparation (SCRS). It protects you if the study enrolls slowly or is cancelled.
  • Screen failures. Tie payment to your expected rate. The industry average is 36.3%, and 57% in CNS trials (Tufts CSDD). A cap far below that guarantees unpaid work.
  • Recruitment funding. Ask for a line for advertising and physician outreach, rather than absorbing it.
  • Overhead. Institutions publish rates; Penn applies a 39% indirect rate to industry studies (Penn Medicine). Know your own rate and include it.
  • Payment terms and holdback. In SCRS's 2023 survey, 51% of sites had monthly payment agreements and the most common holdback was 10 to 14% of earned revenue (IntuitionLabs, citing SCRS). Penn's guidance is that holdback should not exceed 10% (Penn Medicine).

How does the negotiation usually go?

Counter proposals tend to narrow on a few contested lines: per patient rates on the highest effort visits, screen failure terms, startup payment timing, and holdback percentage (CASRAI). Prioritize the two or three that matter most for this protocol and concede on the rest.

How does this connect to recruitment?

A funded recruitment line changes what you can do: physician outreach, ads, or community events become study costs instead of site losses. See what physician referral outreach costs.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Society for Clinical Research Sites, Site Finances White Paper (2024)
  2. SCRS 2024 Global Site Landscape results, Site Solutions Summit
  3. UNC TraCS, "An Introduction to Industry Clinical Trial Budget and Contract Negotiation"
  4. Society for Clinical Research Sites, Site Resource for Invoiceables (2022)
  5. Applied Clinical Trials, "Can Recruitment and Retention Get Any Worse?" (Tufts CSDD screen failure study)
  6. University of Pennsylvania Perelman School of Medicine, Budget Preparation and Development
  7. IntuitionLabs, "Clinical Trial Site Payment Benchmarks 2026" (citing the SCRS 2023 Site Landscape Survey)
  8. CASRAI, "Clinical Trial Budget Negotiation: Strategy for Sites and Sponsors"